Co-Diagnostics (CODX) Investor presentation summary

Company background and vision

• Founded in 2013 in Salt Lake City, Utah, with approximately 85 employees and joint ventures in India and Saudi Arabia.

• Listed on NASDAQ in 2017 and holds patents for Co-Primers technology since 2018.

• Ranked as the 6th fastest growing company in Utah in 2024.

• Sold approximately 35 million tests and generated around $217 million in revenue.

• Aims to democratize access to affordable, real-time molecular diagnostics to improve healthcare outcomes.

Technology and product platform

• Proprietary Co-Primers technology reduces non-specific amplification and enables efficient multiplexing.

• PCR platform is compact, affordable, and delivers results in about 30 minutes via a mobile app.

• Protected by over 20 US and international patents, trade secrets, and copyrights.

• Advanced test design uses machine learning and predictive algorithms for optimization.

• Cloud reporting enables real-time data aggregation and remote result sharing.

Product offerings and applications

• Offers Logix Smart PCR test kits, Vector Smart kits for mosquito control, and the Co-Dx Box qPCR cycler.

• Tests cover infectious diseases such as COVID-19, Flu A/B, RSV, HPV, and MTB.

• Designed for home, point-of-care, and laboratory settings, with over 200 Co-Dx boxes deployed.

• Results are accessible via smartphone and cloud, supporting rapid diagnosis and treatment.